Information from the MS Trust
The Star-MS trial aims to compare the efficacy and safety of HSCT against Ofatumumab (Kesimpta), Cladribine (Mavenclad), Ocrelizumab (Ocrevus) and Alemtuzumab (Lemtrada), four ‘highly effective’ disease modifying drugs (DMDs). The study will be operating across 19 hospital sites across the UK, and aims to recruit 198 participants.
There is growing evidence that Autologous Haematopoietic Stem Cell Transplantation (aHSCT or HSCT) is an effective treatment for relapsing remitting MS. However, there has not yet been a direct comparison of HSCT against the most effective disease modifying drugs currently available. This makes it hard to assess the relative risks and benefits of HSCT for people with MS.
Click here to visit the MS Trust site
Click here to visit the Star MS site
